Tevogen Bio Holdings Inc. Warrant - TVGNW STOCK NEWS

Tevogen Bio (Nasdaq: TVGN) has partnered with Microsoft to advance its oncology treatment pipeline through AI-driven target identification for Human Papilloma Virus (HPV). The company is developing TVGN 920, its first oncology product, using its proprietary ExacTcell™ technology to create HPV-specific cytotoxic T cell (CTL) treatments. The technology, previously successful with SARS-CoV-2-specific CTLs, is being adapted for HPV treatment, targeting a condition that affects 5.5 million women annually, with 200,000 diagnosed with high-grade dysplasia. Tevogen.AI utilizes Microsoft's advanced tools to analyze HPV genome proteins and identify potential CTL targets for clinical trials.

Tevogen Bio (Nasdaq: TVGN) has appointed Anthony Tarantino as its new Patient Advocate. Tarantino, former President of the Newark Fire Officers Union and Legislative Vice President of the Professional Firefighters Association of New Jersey, brings extensive experience in firefighter safety and community advocacy. His notable achievement includes securing legislation for mandatory cancer screenings for firefighters in New Jersey. In his new role, Tarantino will focus on supporting immunocompromised cancer patients and those affected by Long COVID, working alongside Tevogen's leadership team to enhance patient engagement and advocacy programs as the company advances its investigational therapy, TVGN 489.

Tevogen Bio announces expansion of its Microsoft partnership to integrate AI and machine learning into preclinical processes. Through Tevogen.AI, the company aims to accelerate drug development and reduce costs through two key objectives: applying machine learning to expand their ExacTcell™ preclinical pipeline and developing proprietary algorithms to decode HLA-T cell interactions using Microsoft's AI tools. The company anticipates an initial 10% reduction in development timelines, potentially reaching 30% with further automation, significantly impacting the current 10-12 year, $1-3 billion drug development process.

Tevogen Bio (Nasdaq: TVGN) has regained compliance with Nasdaq's minimum bid price requirement without implementing a reverse stock split. The company maintained a closing bid price above $1.00 for 10 consecutive trading days, reaching $3.05 on October 25, 2024. CEO Ryan Saadi emphasized the company's commitment to preserving shareholder value through efficient financing strategies.

The clinical-stage biotech, developing off-the-shelf T cell therapeutics, forecasts $1 billion in oncology revenue for 2026 launch year, with a 5-year estimate of $10-14 billion. Their Specialty Care division projects similar launch year revenue with a 5-year estimate of $18-22 billion. The company recently joined Microsoft for Startups with their Tevogen.AI initiative.

Tevogen Bio (Nasdaq: TVGN) has signed a Letter of Intent with CD8 Technology to establish a $50 million R&D and manufacturing facility. The facility will support pre-clinical research and GMP manufacturing capabilities, with staffing provided by Tevogen. This strategic move aims to overcome capital and time barriers typically associated with building GMP capabilities at scale, potentially accelerating research and manufacturing processes. The company emphasizes that this arrangement will have no impact on shareholder equity while supporting their growth agenda.

Tevogen Bio (Nasdaq: TVGN) has provided additional guidance on TVGN 489, the first clinical product of their ExacTcell™ technology. The therapy is designed to treat SARS-CoV-2 infections in immunocompromised oncology patients and certain PASC patients. The company plans market entry by end of 2026. The pipeline includes treatments for various cancers (TVGN 920 for cervical cancer prevention, TVGN 930 for EBV-associated lymphomas, TVGN 960 for mouth and throat cancer) and multiple sclerosis (TVGN 601). TVGN 489's development was achieved at lower costs compared to industry standards, and positive clinical trial results have been reported.

Tevogen Bio (Nasdaq: TVGN) announces that its AI division, Tevogen AI, has joined Microsoft for Startups. This partnership aims to accelerate drug development and reduce costs by leveraging Microsoft's ecosystem and AI technology. The collaboration aligns with industry projections from The McKinsey Global Institute, which estimates Generative AI could generate $60-110 billion annually in economic value for pharmaceutical and medtech companies, with $18-30 billion attributed to commercial functions.

Tevogen Bio (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech, is set to provide important updates by the end of this week. These updates include:

1. Timelines for the previously announced revenue forecast for Tevogen Oncology and Tevogen Specialty Care therapeutic areas.

2. Details on Tevogen AI, their proprietary artificial intelligence initiative aimed at reducing drug development costs, accelerating drug discovery, and delivering therapies to large patient populations.

3. Information on clinical and commercial manufacturing progress.

The company had previously forecasted approximately $1 billion in revenue for each therapeutic area in their respective launch years, with a 5-year combined estimate between $28 billion and $36 billion.

Tevogen Bio, a clinical-stage specialty immunotherapy biotech (Nasdaq: TVGN), has announced its top-line revenue forecast for its specialty care pipeline. The company projects nearly $1 billion in revenue in its launch year and a cumulative 5-year estimate between $18 billion and $22 billion. This forecast is in addition to Tevogen Bio's Oncology therapeutic area projections of $1 billion in the launch year and $10–$14 billion over the first five years.

The forecast reflects Tevogen's unique, faster, and cost-efficient drug development model, which could serve as a blueprint for sustainable medical innovation. The company's pipeline includes treatments for SARS-CoV-2 infections in various patient groups, Long COVID, cervical cancer prevention, EBV-associated lymphomas, mouth and throat cancer, and multiple sclerosis.